Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

BACKGROUND: Several phase 3 studies reported positive results for combinations of Immune-Oncology (IO) and Vascular Endothelial Growth Factor (VEGF) targeted therapies in patients with metastatic clear cell Renal Cell Carcinoma (ccRCC). However, there are limited data on outcomes to systemic therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ged, Yasser, Gupta, Ruby, Duzgol, Cihan, Knezevic, Andrea, Shapnik, Natalie, Kotecha, Ritesh, Voss, Martin H., Feldman, Darren R., Akin, Oguz, Patil, Sujata, Motzer, Robert J., Rini, Brian I., Lee, Chung-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331268/
https://www.ncbi.nlm.nih.gov/pubmed/32616076
http://dx.doi.org/10.1186/s12894-020-00647-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331268/
https://www.ncbi.nlm.nih.gov/pubmed/32616076
http://dx.doi.org/10.1186/s12894-020-00647-w

Ejemplares similares